Lalani Falak, Young Eric H, Panchal Rupesh M, Reveles Kelly R
College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
Pharmacotherapy Education & Research Center, UT Health San Antonio, San Antonio, Texas, USA.
Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa353. doi: 10.1093/ofid/ofaa353. eCollection 2020 Sep.
infection (CDI) is primarily mediated by alterations in the host gut ecosystem. While antibiotic use is the primary risk factor for CDI, other medications that modulate the gut ecosystem, particularly those targeting the gut-brain axis, could impact CDI risk. This study aimed to investigate the association between recent antidepressant and gamma-aminobutyric acid (GABA)-ergic medication use with CDI risk in a national cohort of United States veterans.
This was a retrospective case-control study of patients seen in Veterans Health Administration facilities from October 2002 to September 2014. CDI and non-CDI control patients were propensity score matched 1:1 using a maximum caliper of 0.0001. Antidepressant and GABAergic medication use 90 days before cohort inclusion were analyzed for CDI association using bivariable and multivariable logistic regression models.
A total of 85 831 patients were included, and 9287 CDI and 9287 control patients were propensity score matched. Antidepressant use overall was not significantly associated with CDI risk (odds ratio [OR], 1.05; 95% CI, 0.98-1.12), although GABAergic medication use was associated with increased risk (OR, 1.81; 95% CI, 1.70-1.92). In multivariable models of individual medications/classes, benzodiazepines had the strongest CDI association (OR, 1.91; 95% CI, 1.77-2.07). SSRIs (OR, 0.88; 95% CI, 0.81-0.95) and bupropion (OR, 0.67; 95% CI, 0.57-0.78) were negatively associated with CDI.
In this national study of veterans, GABAergic medication use was a positive predictor of CDI risk, though antidepressant use was not. Further research is needed to understand biological mechanisms, and confirmatory studies are needed to validate these findings.
艰难梭菌感染(CDI)主要由宿主肠道生态系统的改变介导。虽然抗生素使用是CDI的主要危险因素,但其他调节肠道生态系统的药物,特别是那些针对肠-脑轴的药物,可能会影响CDI风险。本研究旨在调查美国退伍军人全国队列中近期使用抗抑郁药和γ-氨基丁酸(GABA)能药物与CDI风险之间的关联。
这是一项对2002年10月至2014年9月在退伍军人健康管理局设施中就诊的患者进行的回顾性病例对照研究。CDI患者和非CDI对照患者采用倾向评分1:1匹配,最大卡尺为0.0001。使用双变量和多变量逻辑回归模型分析队列纳入前90天的抗抑郁药和GABA能药物使用与CDI的关联。
共纳入85831例患者,9287例CDI患者和9287例对照患者进行了倾向评分匹配。总体而言,抗抑郁药使用与CDI风险无显著关联(优势比[OR],1.05;95%可信区间[CI],0.98-1.12),尽管GABA能药物使用与风险增加相关(OR,1.81;95%CI,1.70-1.92)。在个体药物/类别的多变量模型中,苯二氮䓬类药物与CDI的关联最强(OR,1.91;95%CI,1.77-2.07)。选择性5-羟色胺再摄取抑制剂(SSRIs)(OR,0.88;95%CI,0.81-0.95)和安非他酮(OR,0.67;95%CI,0.57-0.78)与CDI呈负相关。
在这项针对退伍军人的全国性研究中,GABA能药物使用是CDI风险的正向预测因子,而抗抑郁药使用则不是。需要进一步研究以了解其生物学机制,还需要进行验证性研究以证实这些发现。